<scp>EZB</scp> ‐type diffuse large B‐cell lymphoma cell lines have superior migration capabilities compared to <scp>MCD</scp> ‐type

Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent aggressive B-cell lymphoma. The group is heterogeneous and the outcome is variable. A variety of approaches have been employed with the objective of improving the stratification of DLBCL patients according to their prognosis, based on the cell of origin. Recently, distinct genetic subtypes of DLBCL have been identified. Given the importance of cell migration in immune cells, the objective of this study was to ascertain whether different genetic subtypes of DLBCL exhibit disparate migration abilities. MCD- and EZB-type DLBCL cell lines were subjected to testing to ascertain their basal velocity in straight microchannels and their ability to overcome tight constrictions of 2 μm. The EZB-type cell lines showed superior basal migration velocity and constriction passage time, and a similar trend was observed in live cell imaging of native human DLBCL tissue. In addition, MCD-type DLBCL exhibited significantly elevated levels of nuclear lamin A/C, which is responsible for the stiffness of the nuclear envelope and could thus explain the disparate migration behaviours observed among these subtypes. Our study suggests that different genetic subtypes of DLBCL may not only influence the outcome after therapy but also the motility of the tumour cells.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2024-10-02
DOI
https://doi.org/10.1111/bjh.19778
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

EZB ‐type diffuse large B‐cell lymphoma cell lines have superior migration capabilities compared to MCD ‐type

Aresu Sadeghi Shoreh Deli, Sonja Scharf, Thomas Oellerich, Andreas Loth et al.
1 citations
British Journal of Haematology
Lymphoma Diagnosis and Treatment
0.42
article

EZB ‐type diffuse large B‐cell lymphoma cell lines have superior migration capabilities compared to MCD ‐type

Aresu Sadeghi Shoreh Deli, Sonja Scharf, Thomas Oellerich, Andreas Loth, Falko Fend, Hendrik Schäfer, Sylvia Hartmann, Leticia Quintanilla‐Martinez, Vivienne van Oostendorp, Martin‐Leo Hansmann, M.Sc. RASHA A. ABDEL NOOR WAFAA M. SHERIF, Matthieu Piel
article en
1 citations

Abstract

Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent aggressive B-cell lymphoma. The group is heterogeneous and the outcome is variable. A variety of approaches have been employed with the objective of improving the stratification of DLBCL patients according to their prognosis, based on the cell of origin. Recently, distinct genetic subtypes of DLBCL have been identified. Given the importance of cell migration in immune cells, the objective of this study was to ascertain whether different genetic subtypes of DLBCL exhibit disparate migration abilities. MCD- and EZB-type DLBCL cell lines were subjected to testing to ascertain their basal velocity in straight microchannels and their ability to overcome tight constrictions of 2 μm. The EZB-type cell lines showed superior basal migration velocity and constriction passage time, and a similar trend was observed in live cell imaging of native human DLBCL tissue. In addition, MCD-type DLBCL exhibited significantly elevated levels of nuclear lamin A/C, which is responsible for the stiffness of the nuclear envelope and could thus explain the disparate migration behaviours observed among these subtypes. Our study suggests that different genetic subtypes of DLBCL may not only influence the outcome after therapy but also the motility of the tumour cells.

British Journal of HaematologyVol. 205(6)
Goethe University Frankfurt (DE), Centre National de la Recherche Scientifique (FR), German Cancer Research Center (DE), Heidelberg University (DE), Université Paris Sciences et Lettres (FR), Frankfurt Institute for Advanced Studies (DE), Institut Pierre-Gilles de Gennes pour la Microfluidique (FR), University Hospital Frankfurt (DE), Frankfurt Cancer Institute (DE), Biologie cellulaire et Cancer (FR), University of Duisburg-Essen (DE), Institut Curie (FR), University of Tübingen (DE)
Deutsche Forschungsgemeinschaft
Reduced inequalities
Openalex Percentile: Top 34%
Lymphoma Diagnosis and Treatment
0.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.